DOPPL is now part of InSphero
Bringing DOPPL’s Expertise and Technology into InSphero
DOPPL is part of InSphero, bringing together complementary technologies, scientific expertise, and customer support under one unified organization.
The technologies and know-how you know from DOPPL continue within the InSphero Group, now supported by a broader portfolio of human-relevant 3D in vitro solutions and one streamlined customer experience.
Gri3D® Technology & Plates, Now Part of InSphero
Gri3D® technology combines hydrogel-based microcavity plates with a scalable approach to reproducible spheroid and organoid culture, treatment, and analysis. Now part of the InSphero portfolio, Gri3D® expands the range of 3D cell culture solutions available for applications from model generation to higher-throughput screening and imaging.
Spheroid and Organoid Technologies
Click to discover
Spheroid and Organoid Model Development
Click to discover
Continued Support for DOPPL Customers
As part of the integration, DOPPL’s technologies, scientific expertise, and customer relationships continue within InSphero. Existing projects remain supported, while customers now benefit from access to InSphero’s broader portfolio of human-relevant 3D in vitro models, technologies, and services.
For questions related to ongoing projects, please reach out to your usual contact from the DOPPL team.
For new inquiries or product information, the InSphero team is your central point of contact.
Regulatory information
Certain regulated research activities continue to be performed exclusively by DOPPL SA, Lausanne, Switzerland, as the responsible legal entity and under its sole scientific and operational responsibility, in accordance with ethical approval CER-VD 2024-02364.
Explore InSphero’s 3D Cell Culture Portfolio
Discover InSphero’s portfolio of human-relevant 3D in vitro models and technologies, supporting research from safety assessment to disease modeling and efficacy testing.
